Crescita Therapeutics Inc.

TSX:CTX 주식 보고서

시가총액: CA$10.3m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Crescita Therapeutics 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Serge Verreault

최고 경영자

CA$462.3k

총 보상

CEO 급여 비율81.1%
CEO 임기7.2yrs
CEO 소유권3.8%
경영진 평균 재임 기간데이터 없음
이사회 평균 재임 기간8.3yrs

최근 관리 업데이트

We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope

May 30
We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope

Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)

May 05
Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)

Recent updates

We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope

May 30
We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope

Why Investors Shouldn't Be Surprised By Crescita Therapeutics Inc.'s (TSE:CTX) 33% Share Price Surge

Jan 04
Why Investors Shouldn't Be Surprised By Crescita Therapeutics Inc.'s (TSE:CTX) 33% Share Price Surge

Is Crescita Therapeutics (TSE:CTX) Using Debt Sensibly?

Nov 18
Is Crescita Therapeutics (TSE:CTX) Using Debt Sensibly?

Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)

May 05
Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)

Crescita Therapeutics Inc.'s (TSE:CTX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 10
Crescita Therapeutics Inc.'s (TSE:CTX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

CEO 보상 분석

Serge Verreault 의 보수는 Crescita Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-CA$2m

Dec 31 2023CA$462kCA$375k

-CA$2m

Sep 30 2023n/an/a

-CA$658k

Jun 30 2023n/an/a

CA$819k

Mar 31 2023n/an/a

CA$1m

Dec 31 2022CA$704kCA$375k

CA$862k

Sep 30 2022n/an/a

CA$627k

Jun 30 2022n/an/a

-CA$468k

Mar 31 2022n/an/a

-CA$1m

Dec 31 2021CA$651kCA$375k

-CA$1m

Sep 30 2021n/an/a

-CA$3m

Jun 30 2021n/an/a

CA$2m

Mar 31 2021n/an/a

CA$95k

Dec 31 2020CA$659kCA$338k

CA$37k

Sep 30 2020n/an/a

CA$146k

Jun 30 2020n/an/a

-CA$4m

Mar 31 2020n/an/a

CA$1m

Dec 31 2019CA$823kCA$336k

CA$2m

Sep 30 2019n/an/a

CA$5m

Jun 30 2019n/an/a

CA$6m

Mar 31 2019n/an/a

CA$3m

Dec 31 2018CA$555kCA$287k

CA$2m

Sep 30 2018n/an/a

-CA$9m

Jun 30 2018n/an/a

-CA$10m

Mar 31 2018n/an/a

-CA$9m

Dec 31 2017CA$734kCA$173k

-CA$11m

보상 대 시장: Serge 의 총 보상 ($USD 337.20K )은 Canadian 시장( $USD 175.07K ).

보상과 수익: Serge 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Serge Verreault

7.2yrs

테뉴어

CA$462,268

보상

Mr. Serge Verreault, BA, MBA has been the President of Crescita Therapeutics Inc. since April 17, 2017 and its Chief Executive Officer since April 2, 2018 and is Director from June 20, 2023. Mr. Verreault...

이사회 구성원

이름위치테뉴어보상소유권
Serge Verreault
Presidentless than a yearCA$462.27k3.82%
CA$ 393.1k
Anthony Dobranowski
Independent Director8.3yrsCA$74.75k0.51%
CA$ 53.0k
John London
Independent Vice Chairman8.3yrsCA$60.75k1.0%
CA$ 102.6k
Daniel Chicoine
Non-Executive Chairman8.3yrsCA$72.25k5.44%
CA$ 560.4k
Deborah Shannon-Trudeau
Independent Non-Executive Director2.6yrsCA$56.75k데이터 없음

8.3yrs

평균 재임 기간

경험이 풍부한 이사회: CTX 의 이사회는 경험(평균 재직 기간 8.3 년)으로 간주됩니다.